Pulaski and colleagues have shown that IL-3 enhances tumor rejection via development of cytotoxic effectors by a mechanism that requires CD4+ cells [19], and they demonstrated that IL-3 induced the antigen cross presentation ability of macrophages [27], [28]. The gene discussed is CD4; the disease is neoplasm.